Skip to content

To explore the effectiveness and safety of medical adhesives used in thoracoscopic lung resection:a multicenter, prospective, randomized controlled study

To explore the effectiveness and safety of medical adhesives used in thoracoscopic lung resection:a multicenter, prospective, randomized controlled study

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500105854
Enrollment
Unknown
Registered
2025-07-14
Start date
2024-11-14
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pulmonary nodule

Interventions

Experimental group:Use medical adhesives to seal the incision margin and lung tissue wounds
Control group:No medical adhesives.

Sponsors

Shenzhen Third People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.80 years old >= age>=18 years old, gender is not limited; 2. Preoperative diagnosis is mixed GGO or pure GGO with maximum lung diameter <=2cm and CTR <=0.25 found on chest CT; 3. Pumornary nodules located in the peripheral 1/3 of the lung, who are to undergo thoracoscopic lung wedge resection; 4. The patient gave informed consent and voluntarily sign the "Subject Informed Consent Form"

Exclusion criteria

Exclusion criteria: 1. Performing systematic mediastinal lymph node dissection during surgery; 2. Convert to thoracotomy during operation; 3. Those with severe pleural adhesion; 4. Those with severe coagulation abnormalities; 5. Patients with severe chronic obstructive pulmonary disease and emphysema; 6. Severe basic diseases of the heart, lungs, liver, kidneys and other organs; 7. Those whose life expectancy is less than 12 months; 8. Patients who are pregnant or lactating and in a life-critical situation; 9. Patients who have participated in any other clinical trials within 1 month; 10. Patients who have received lung anti-tumor treatment (radiotherapy, ablation, targeted, immunotherapy, chemotherapy) before surgery

Design outcomes

Primary

MeasureTime frame
Extubation rate 4 hours after surgery;

Secondary

MeasureTime frame
Percentage of patients without air leakage after surgery;Duration of postoperative air leakage (h);Air leakage at 12, 24, and 48 hours after surgery (ml);Postoperative pig tail tube extraction time (h);Postoperative hospital stay (days);Postoperative pain score (VAS score at rest and cough at 12h, 24h, 48h postoperatively);Postoperative re-insertion rate;

Countries

China

Contacts

Public ContactQiao Kun

Shenzhen Third People's Hospital

szqiaokun@163.com+86 180 2538 8707

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026